NASDAQ:UPB Upstream Bio Q3 2026 Earnings Date & Estimates $4.70 0.00 (0.00%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$4.71 +0.01 (+0.21%) As of 10/9/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Upstream Bio is scheduled to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens. The conference call is scheduled for 7:00 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 4, 2026TimeBefore Market OpensConference Call7:00 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Upstream Bio in Q3 2026Upstream Bio is expected to post earnings of -$0.7286 per share on revenue of $0.52 million. In the same quarter a year earlier Upstream Bio reported -$0.63 per share on revenue of $0.68 million. Upstream Bio last reported on August 11, 2026, posting -$0.73 per share and beating the -$0.7444 consensus estimate. Upstream Bio has beaten the consensus EPS estimate in 2 of its last 7 quarters.Consensus EstimatesConsensus EPS-$0.7286Expected Revenue$0.52 millionPrior-Year EPS-$0.63Prior-Year Revenue$0.68 millionExpected Revenue Growth-23.6%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.73 (Beat by +$0.0144)Last Quarter Revenue$0.77 millionEPS Beat Rate2 of last 7 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Upstream Bio Q3 2026 Earnings FAQ When does Upstream Bio report Q3 2026 earnings? Upstream Bio (NASDAQ:UPB) is scheduled to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens. What time is Upstream Bio's Q3 2026 earnings call? Upstream Bio's Q3 2026 earnings conference call is scheduled for Wednesday, November 4, 2026 at 7:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Upstream Bio? Analysts expect Upstream Bio to post earnings of -$0.7286 per share for Q3 2026. How much revenue is Upstream Bio expected to report? The consensus revenue estimate for Upstream Bio is $0.52 million for Q3 2026. Upstream Bio Earnings HeadlinesUpstream Bio Reports Phase 2 VALIANT Trial Results Showing Verekitug Reduced Severe Asthma Exacerbations by 56% with Quarterly DosingSeptember 8, 2026 | quiverquant.comQUpstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026September 8, 2026 | globenewswire.comMy biggest prediction yet?!James Altucher called Facebook's rise past 100 billion dollars in 2007 and Apple's run to a trillion years later, both times facing skepticism. Now he's tracking a new Elon Musk production facility that could begin operations as soon as October 21, tied to what he calls a potential 2 quadrillion dollar opportunity by 2040, based on Dallas Fed data. Altucher has put the full story and drone footage into one presentation. | Paradigm Press (Ad)Analysts Are Bullish on These NA Stocks: Upstream Bio, Inc. (UPB), Fervo Energy Company Class A (FRVO)September 2, 2026 | theglobeandmail.comUpstream Bio on Track to Begin Two Phase 3 Verekitug Trials in Q1 2027September 1, 2026 | finance.yahoo.comUpstream Bio Outlines Phase 3 Plans for VerekitugSeptember 1, 2026 | tipranks.comSee More Upstream Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Upstream Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Upstream Bio and other key companies, straight to your email. Email Address About Upstream BioUpstream Bio (NASDAQ:UPB) is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases. The company’s research is centered on targeting biological pathways involved in immune-system activation and chronic inflammation, with an emphasis on conditions affecting the airways. Upstream Bio’s lead product candidate is verekitug, formerly known as UPB-101. Verekitug is a long-acting monoclonal antibody designed to selectively inhibit thymic stromal lymphopoietin, or TSLP, a cytokine that contributes to the development and persistence of inflammation. The company is evaluating verekitug as a potential treatment for inflammatory respiratory conditions, including asthma and chronic rhinosinusitis with nasal polyps. Upstream Bio advances its programs through clinical development and collaborations with research and healthcare organizations. The company is based in the United States and focuses on serving patients with significant unmet needs in immune-mediated and inflammatory diseases. As a clinical-stage biotechnology company, its operations remain primarily centered on research, clinical trials and the development of potential future therapies.View Upstream Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes NextDelta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
